Treats metastatic non-small cell lung cancer (NSCLC). Sold as Zykadia. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 2 applications for Ceritinib (sold as Zykadia), first approved Apr 29, 2014, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Zykadia | Part D | $4.1M | -10% | 43 |
| Ceritinib Treatment for Recurrent MeningiomasRecurrent Meningioma, Grade I and Grade II · Kevin Petrecca | Phase 2 | Not yet recruiting | Oct 23, 2026 |
| Using Tumor Models to Determine TreatmentsPancreatic Ductal Carcinoma, Advanced Cancer · University Health Network, Toronto | Phase 2 | Recruiting | Feb 6, 2025 |
| Antineoplastic Drugs in Elderly PatientsCancer · Shandong University | — | Recruiting | Jul 20, 2022 |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)Locally Advanced Solid Tumor, Metastatic Solid Tumor · Nuvalent Inc. | Phase 1 / Phase 2 | Recruiting | May 20, 2022 |
| Improving Public Cancer Care by Implementing Precision Medicine in NorwayCancer Metastatic · Oslo University Hospital | Phase 2 | Recruiting | Mar 26, 2021 |
| Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationNon Small Cell Lung Cancer, EGFR Gene Mutation · Hunan Province Tumor Hospital | Phase 2 | Recruiting | Mar 26, 2020 |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCNon-small Cell Lung Cancer, Lung Cancer · H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | Active, not recruiting | Aug 2, 2018 |
| Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored StudyALK Positive Malignancies · Novartis Pharmaceuticals | Phase 4 | Active, not recruiting | Oct 23, 2015 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Novartis